Evotec SE (NASDAQ: EVO) announced on January 2, 2026, the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations.
In this newly created strategic role, Dr. Fakih will lead an integrated function designed to synchronize Evotec’s corporate messaging with its capital markets strategy.
She will report directly to CEO Dr. Christian Wojczewski, who took the helm in mid-2024 following a turbulent period of leadership transition for the German drug discovery giant.
The reorganization follows the departure of Volker Braun, who oversaw the company’s investor relations and ESG (Environmental, Social, and Governance) efforts for the past five years.
By merging communications and IR, Evotec aims to provide greater clarity and consistency as it executes its "Priority Reset" strategy—a plan focused on capital efficiency and the high-growth "Just – Evotec Biologics" segment.
Dr. Fakih joins Evotec with over 15 years of experience in the life sciences sector.
Most recently, she served as Vice President of Investor Relations at CureVac, where she navigated high-profile capital markets activities.
Her resume also includes senior leadership roles at MorphoSys and QIAGEN, giving her deep familiarity with both European and U.S. listing environments.
She holds a PhD in Chemistry, providing her with the technical depth required to articulate Evotec’s complex R&D platforms.